Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

The road we must take: multidisciplinary team science.

Disis ML, Slattery JT.

Sci Transl Med. 2010 Mar 10;2(22):22cm9. doi: 10.1126/scitranslmed.3000421.

PMID:
20374998
2.

The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study.

Kuffner EK, Green JL, Bogdan GM, Knox PC, Palmer RB, Heard K, Slattery JT, Dart RC.

BMC Med. 2007 May 30;5:13.

3.

Improved detection and characterization of adrenal disease with PET-CT.

Elaini AB, Shetty SK, Chapman VM, Sahani DV, Boland GW, Sweeney AT, Maher MM, Slattery JT, Mueller PR, Blake MA.

Radiographics. 2007 May-Jun;27(3):755-67. Review.

PMID:
17495290
4.

Disposition of acetaminophen at 4, 6, and 8 g/day for 3 days in healthy young adults.

Gelotte CK, Auiler JF, Lynch JM, Temple AR, Slattery JT.

Clin Pharmacol Ther. 2007 Jun;81(6):840-8. Epub 2007 Mar 21.

PMID:
17377528
5.

Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach.

Salinger DH, McCune JS, Ren AG, Shen DD, Slattery JT, Phillips B, McDonald GB, Vicini P.

Clin Cancer Res. 2006 Aug 15;12(16):4888-98.

6.

Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial.

Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC.

JAMA. 2006 Jul 5;296(1):87-93.

PMID:
16820551
7.

Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry.

Kalhorn TF, Howald WN, Cole S, Phillips B, Wang J, Slattery JT, McCune JS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 1;835(1-2):105-13. Epub 2006 Apr 11.

PMID:
16581318
8.

Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant.

McDonald GB, McCune JS, Batchelder A, Cole S, Phillips B, Ren AG, Vicini P, Witherspoon R, Kalhorn TF, Slattery JT.

Clin Pharmacol Ther. 2005 Sep;78(3):298-308.

PMID:
16153400
9.

Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.

Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT, Cole S, Nash RA, Storb RF, Georges GE.

Blood. 2005 Dec 15;106(13):4381-8. Epub 2005 Sep 6.

10.

A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.

Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R.

Biol Blood Marrow Transplant. 2005 Jul;11(7):495-505.

11.

A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells.

Kalhorn TF, Ren AG, Slattery JT, McCune JS, Wang J.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jun 25;820(2):243-50. Epub 2005 Apr 21.

PMID:
15899377
12.

Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants.

Bensinger WI, Buckner CD, Lilleby K, Holmberg L, Storb R, Slattery JT.

Oncology. 2004;67(5-6):368-75.

PMID:
15713992
13.

The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283).

Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD.

Clin Pharmacol Ther. 2004 Dec;76(6):579-87.

PMID:
15592329
14.

The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283).

Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD.

Clin Pharmacol Ther. 2004 Oct;76(4):313-22.

PMID:
15470330
15.

Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard.

Qiu R, Yao A, Vicini P, McDonald GB, Batchelder AL, Bouvier ME, Cole SL, Slattery JT.

Clin Pharmacol Ther. 2004 Sep;76(3):270-80.

PMID:
15371987
16.

How do smectic liquid crystals of different molecular length mix in thin films?

Keymeulen HR, de Jeu WH, Slattery JT, Veum M.

Eur Phys J E Soft Matter. 2002 Dec;9(5):443-6.

PMID:
15011091
17.

ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat.

Qiu R, Kalhorn TF, Slattery JT.

J Pharmacol Exp Ther. 2004 Mar;308(3):1204-12. Epub 2003 Nov 14.

PMID:
14617693
18.

Cyclophosphamide metabolism is affected by azole antifungals.

Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, McDonald GB.

Blood. 2004 Feb 15;103(4):1557-9. Epub 2003 Sep 22.

PMID:
14504090
19.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR.

Blood. 2003 Dec 1;102(12):3912-8. Epub 2003 Aug 14.

PMID:
12920019
20.

Transiently altered acetaminophen metabolism after liver transplantation.

Park JM, Lin YS, Calamia JC, Thummel KE, Slattery JT, Kalhorn TF, Carithers RL Jr, Levy AE, Marsh CL, Hebert MF.

Clin Pharmacol Ther. 2003 Jun;73(6):545-53.

PMID:
12811364
21.

Re: intravenous versus oral busulfan--perhaps not as different as suggested.

Slattery JT.

Biol Blood Marrow Transplant. 2003 Apr;9(4):282-4. No abstract available.

22.

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.

Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, McDonald GB, Nichols WG, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C.

Blood. 2003 Aug 1;102(3):820-6. Epub 2003 Apr 3.

PMID:
12676781
23.

Pharmacological considerations of primary alkylators.

McCune JS, Slattery JT.

Cancer Treat Res. 2002;112:323-45. Review. No abstract available.

PMID:
12481723
25.

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.

McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T.

Blood. 2003 Mar 1;101(5):2043-8. Epub 2002 Oct 24.

PMID:
12406916
26.

Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.

McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, Anasetti C, Risler L, Sultan D, Slattery JT.

Bone Marrow Transplant. 2002 Aug;30(3):167-73.

27.

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.

Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR.

Blood. 2002 Aug 15;100(4):1201-7.

PMID:
12149198
28.

Selective mitochondrial glutathione depletion by ethanol enhances acetaminophen toxicity in rat liver.

Zhao P, Kalhorn TF, Slattery JT.

Hepatology. 2002 Aug;36(2):326-35.

PMID:
12143040
29.

Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.

Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV, Norstad D, Cowan MJ.

Bone Marrow Transplant. 2001 Dec;28(11):1013-8.

30.

Plasma concentration monitoring of busulfan: does it improve clinical outcome?

McCune JS, Gibbs JP, Slattery JT.

Clin Pharmacokinet. 2000 Aug;39(2):155-65. Review.

PMID:
10976660
31.

Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults.

Thummel KE, Slattery JT, Ro H, Chien JY, Nelson SD, Lown KE, Watkins PB.

Clin Pharmacol Ther. 2000 Jun;67(6):591-9.

32.

An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.

Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L, Risler LJ, Bostrom B, Cowan MJ.

Bone Marrow Transplant. 2000 May;25(9):925-30.

33.

Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation.

Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT.

Clin Pharmacol Ther. 2000 Mar;67(3):275-82.

PMID:
10741631
34.

Busulfan clearance in renal failure and hemodialysis.

Ullery LL, Gibbs JP, Ames GW, Senecal FM, Slattery JT.

Bone Marrow Transplant. 2000 Jan;25(2):201-3.

35.

Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.

Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT, Anasetti C, Fefer A, Storb R, Appelbaum FR.

Blood. 2000 Feb 15;95(4):1188-94.

PMID:
10666189
36.

Up-regulation of glutathione S-transferase activity in enterocytes of young children.

Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT.

Drug Metab Dispos. 1999 Dec;27(12):1466-9.

PMID:
10570028
37.

Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection.

Kalhorn TF, Ren S, Howald WN, Lawrence RF, Slattery JT.

J Chromatogr B Biomed Sci Appl. 1999 Sep 24;732(2):287-98.

PMID:
10517350
38.

The impact of obesity and disease on busulfan oral clearance in adults.

Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, Slattery JT.

Blood. 1999 Jun 15;93(12):4436-40.

PMID:
10361142
39.

Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein.

Ren S, Kalhorn TF, Slattery JT.

Drug Metab Dispos. 1999 Jan;27(1):133-7.

PMID:
9884322
40.

Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation.

Slattery JT, Risler LJ.

Ther Drug Monit. 1998 Oct;20(5):543-9. Review.

PMID:
9780133
41.

Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients.

Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, Slattery JT.

Clin Pharmacol Ther. 1998 Sep;64(3):289-301.

PMID:
9757153
42.
43.
44.
45.

Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan.

Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT.

Cancer Res. 1997 Dec 15;57(24):5509-16.

46.
47.

Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization.

Chien JY, Thummel KE, Slattery JT.

Drug Metab Dispos. 1997 Oct;25(10):1165-75.

PMID:
9321520
48.

Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes.

Lee CA, Manyike PT, Thummel KE, Nelson SD, Slattery JT.

Drug Metab Dispos. 1997 Oct;25(10):1150-6.

PMID:
9321518
49.

Characterization of carbamazepine metabolism in a mouse model of carbamazepine teratogenicity.

Amore BM, Kalhorn TF, Skiles GL, Hunter AP, Bennett GD, Finnell RH, Nelson SD, Slattery JT.

Drug Metab Dispos. 1997 Aug;25(8):953-62.

PMID:
9280403
50.

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR.

Blood. 1997 Apr 15;89(8):3055-60.

PMID:
9108427

Supplemental Content

Loading ...
Support Center